Home
overview
As the population ages there is a growing market for therapeutics that smooth the menstrual transition. Osteoporosis is one condition that appears to have an increasing number of sufferers, indeed the rate of bone fracture is increasing at a rate beyond that that can be explained by the ageing population alone. The Osteoporosis Foundation estimates that by 2010 there will be 35 million women with osteoporosis or low bone mass, representing a rapidly expanding market for therapies that combat the disease.

With the recent contraversy over the so-called ‘hormone replacement therapies’ and their side effects, there is an increasing need to look into ways of modifying HRT treatments and into alternative treatments for osteoporosis and menopausal symptoms. One possible way forward seems to be the development of SERMS and non-hormonal solutions. This conference will endeavour to evaluate the real risk associated with HRT, how to manage HRT products in an unstable market and it will look into the potential benefits of other classes of treatment such as bisphosphonates which may pave the way forward.

SMi has identified this as a key time to provide an in-depth evaluation of the epidemiology of osteoporosis and menopausal disorders and to create a forum at which the future market for agents against osteoporosis and other effects of the menopause can be discussed.

A unique opportunity to learn from leading industry experts including:
· Dr Robert Spirtas, Chief, Contraception & Reproductive Health Branch, CPR, NICHD, National Institutes of Health
· Dr Sanjay Kumar, Director, GlaxoSmithKline
· Dr Donato Agnusdei, Osteoporosis Consultant, Europe & Latin America Eli Lilly
· Dr Ji Li, Research Scientist, Amgen
· Dr John Fox, Senior Scientist, NPS Pharmaceuticals
· Prof Andrea Genazzani, Professor & Chairman, International Society of Gynaecological Endocrinology & University of Pisa
· Dr Eugene McCloskey, Clinical Senior Lecturer, Honorary Consultant, Metabolic Bone Diseases, World’s Health Organisation, Collaborating Centre, Metabolic Bone Diseases & University of Sheffield

Key benefits of attending:
DIAGNOSTICS: focus on early detection of osteoporosis
HRT THERAPIES: learn about potential benefits and dangers related to HRT
ALTERNATIVE STRATEGIES: review novel approaches to the treatment of osteoporosis
BONE FORMING AGENTS: understand the use of parathyroid hormone peptides for the treatment of osteoporosis
EXPERIMENTAL AREAS: gain an insight into combination therapies

Conference programme

8:30 Re-registration and Coffee

9:00 Chairperson's Opening Remarks

Dr Juliet Compston

Dr Juliet Compston, Reader in Metabolic Bone Disease and Honorary Consultant Physician, University of Cambridge

9:10 KEYNOTE ADDRESS

Professor Andrea Genazzani

Professor Andrea Genazzani, Chairman & Professor, International Society of Gynaecological Endocrinology & University of Pisa

  • Why is menopause an important issue?
  • What is the role of endocrinology?
  • Ways of effectively preventing or managing some of the problems that can be associated with the menopause
  • How to improve quality of life by preventing the harmful consequences of estrogen hormone deprivation
  • Overview of future strategies
  • 9:40 THE MENOPAUSE, BONE TURNOVER AND METASTATIC RISK OF PRIMARY BREAST CANCER

    Dr Eugene McCloskey

    Dr Eugene McCloskey, Clinical Senior Lecturer & Honorary Consultant, Metabolic Bone Diseases, World’s Health Organisation, Collaborating Centre for Metabolic Bone Diseases & University of SheffieldWorld’s Health Organisation, Collaborating Centre for Metabolic Bone Diseases & University of Sheffield

  • The effects of systematic treatment of breast cancer on bone turnover differ in pre-menopausal women and post-menopausal women
  • Changes in biochemical markers but not bone mineral density appear to be associates with metastatic risk
  • The suppression of bone resorption reduces the risk of bone metastases
  • The incidence of visceral metastases of mortality also appear to be reduced
  • 10:20 DIAGNOSTICS

    Andy Anderson

    Andy Anderson, Managing Director, Crawford Medical

  • Improving the efficiency of monitoring osteoporosis
  • The importance of early detection of osteoporosis
  • Improving screening methods and rates of diagnosis
  • The difficulties involved in producing diagnostic test, in terms of finance etc
  • Lessons learned so far
  • Future strategies
  • 11:00 Morning Coffee

    11:20 ESTABLISHMENT OF RESEARCH AGENDA FOR HRT

    Dr Robert Spirtas

    Dr Robert Spirtas, Chief, Contraceptive & Reproductive Health Branch, CPR, NICHD, National Institutes of Health

  • Health risks of E vs E + P
  • Outcome of NIH meeting
  • New directions in HRT
  • 12:00 HORMONE REPLACEMENT THERAPIES (HRT)

    Dr John Stevenson

    Dr John Stevenson, Reader & Honorary Consultant Physician, Imperial College London

  • Estrogen replacement therapy (ERT)
  • Where does progestogen fit into therapy?
  • What is the role of estrogen in the prevention/treatment of osteoporosis?
  • Androgen therapy
  • Additional potential benefits of HRT
  • 12:40 Networking Lunch

    14:00 PHYTO ESTROGENS: THE OTHER HRT?

    Dr Terttu Haring

    Dr Terttu Haring, Director, Women’s Health, Kendle

  • Menopausal symptom relief
  • Osteoporosis
  • Cardivascular system
  • Endometrium and breast tissue
  • 14:40 COMBINATION THERAPIES

    Dr Juliet Compston

    Dr Juliet Compston, Reader in Metabolic Bone Disease and Honorary Consultant Physician, University of Cambridge

  • Current combination therapies
  • Optimisation and improvements in bone mass and bone strength while minimising side effects
  • Clinical trials of combination of therapeutic agents for osteoporosis
  • Safety assessment
  • Effectiveness of combining therapies for osteoporosis
  • Future strategies for combination therapies
  • 15:20 DISCUSSION SESSION

    Dr Juliet Compston

    Dr Juliet Compston, Reader in Metabolic Bone Disease and Honorary Consultant Physician, University of Cambridge

    Dr Eugene McCloskey

    Dr Eugene McCloskey, Clinical Senior Lecturer & Honorary Consultant, Metabolic Bone Diseases, World’s Health Organisation, Collaborating Centre for Metabolic Bone Diseases & University of SheffieldWorld’s Health Organisation, Collaborating Centre for Metabolic Bone Diseases & University of Sheffield

    16:00 Chairperson's Closing Remarks followed by Afternoon Tea.
    Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Professor Andrea Genazzani

    Professor Andrea Genazzani, Chairman & Professor, International Society of Gynaecological Endocrinology & University of Pisa

    9:10 MANAGEMENT OF OSTEOPOROSIS AT THE PRIMARY CARE

    Dr Irit Yaniv

    Dr Irit Yaniv, Vice President, Research & Development, Sunlight Medical

  • Osteoporosis – prevalent but neglected
  • Osteoporosis and other chronic diseases
  • Physician role in managing osteoporosis
  • The primary care dignostic tools
  • Conflicts and proposed resolution
  • Summary – looking to the future
  • 9:40 NEWER THERAPEUTIC APPROACHES FOR THE TREATMENT OF OSTEOPOROSIS

    Dr Sanjay Kumar

    Dr Sanjay Kumar, Director, GlaxoSmithKline

  • Existing therapies
  • Need for new therapies
  • Review of novel anti-resorptives
  • Review of novel anabolic agents
  • Future possiblities
  • 10:20 NOVEL ANTI-RESORPTIVE THERAPY FOR OSTEOPOROSIS AND OTHER OSTEOLYTIC DISEASES

    Dr Ji Li

    Dr Ji Li, Research Scientist, Amgen

  • Discovery of the signaling pathway
  • Functional genomics and target validation
  • Therapeutic targeting strategy
  • Efficacy in pre-clinical animal models
  • Early proof-of-concept human clinical data
  • 11:00 Morning Coffee

    11:20 INTACT PARATHYROID HORMONE 1-84 AS AN ANABOLIC AGENT IN OSTEOPOROSIS

    Dr John Fox

    Dr John Fox, Senior Scientist, NPS Pharmaceuticals

  • Effects of intact PTH in patients with osteoporosis
  • Effects of intact PTH on cancellous and cortical bone architecture and strength
  • Role of carboxyl-terminal PTH fragments in bone
  • Relevance of osteosarcoma
  • The potential benefits or adverse consequences of combination (together or sequential) anabolic and antiresorptive therapies
  • 12:00 BONE FORMING AGENTS: PARATHYROID HORMONE PEPTIDES

    Dr Donato Agnusdei

    Dr Donato Agnusdei, Osteoporosis Consultant Europe & Latin America, Eli Lilly

  • Teriparatide, from bone cracker to bone builder
  • De novo bone formation after Teriparatide treatment
  • Effects of Teriparatide on bone architecture
  • Anti-fracture efficacy of Teriparatide
  • Combining bone forming and anti-resorptive agents
  • Future treatment strategies for patients with fractures using Teriparatide
  • 12:40 Networking Lunch

    14:00 OSTEOPOROSIS – STAKEHOLDER INSIGHTS

    Victoria Williams

    Victoria Williams, Analyst, Datamonitor

  • How do diagnosis and treatment rates vary by gender and disease severity across the major pharmaceutical markets?
  • How do treatment trends vary by disease severity and what really are the leading drugs in practice? Will this still be the case in five years’ time? What are the most important factors influencing physicians treatment practices?
  • Dominance of the bisphosphonates: how long will Merck’s Fosamax (alendronate) be able to hold onto the market lead? Will P&G/Aventis’ Actonel (risedronate) be its biggest threat, or are there greater dangers in the pipeline?
  • Can Lilly’s Evista (raloxifene) oust hormone therapy in the postmenopausal population?
  • What impact will Lilly’s Forteo (Teriparatide) have on treatment patterns? What factors are affecting uptake and are physicians willing to prescribe the drug?
  • What are the unmet needs in osteoporosis from a physician and patient perspective? What are pharmaceutical companies key strategies for success in this market?
  • 14:40 VITAMIN D ANALOGS

    Dr Lori Plum

    Dr Lori Plum, Director, Research & Development, Deltanoid Pharmaceuticals

  • How does vitamin D work?
  • Past successes and failures in osteoporosis treatment
  • A new class of vitamin D analogs
  • Unique effect of 2MD in bone
  • Future plans of 2MD in bone
  • 15:20 Afternoon Tea

    15:40 IMPACT OF THE WHI-STUDY ON THE HRT MARKET

    Martin Trang

    Martin Trang, Vice President & Head, Business Unit Hormone Therapy & Urology, Orion Pharma

  • General recommendations
  • Concerns
  • Market trends
  • Drivers
  • Outlook
  • 16:20 IMPACT OF PRODUCT PRESENTATION ON OSTEOPOROSIS MARKET

    Kevin Maynard

    Kevin Maynard, Business Development Manager, Imprint Pharmaceuticals

  • Product presentation influencing sales
  • Development of strategies to maximise user acceptance
  • Enchancing presentation of inhalation devices
  • Enchancing the presentation of patches
  • Enhancing injection devices
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.